News Earnings Aspira Pathlab Reports Q3FY26 Net Loss of ₹156.12 Lakhs Against Prior Year ProfitAspira Pathlab Reports Q3FY26 Net Loss of ₹156.12 Lakhs Against Prior Year Profit
Aspira Pathlab & Diagnostics Limited reported a net loss of ₹156.12 lakhs for Q3FY26 against a profit of ₹37.66 lakhs in Q3FY25, with revenue declining 5.33% to ₹511.88 lakhs. For nine months FY26, the company maintained profitability at ₹74.03 lakhs despite a 45.17% decline from ₹135.02 lakhs in the previous year. The Board approved a ₹5 crore related party transaction with Yashraj Research Foundation subject to member approval.
*this image is generated using AI for illustrative purposes only.
Aspira pathlab & Diagnostics Limited announced its unaudited standalone financial results for the third quarter and nine months ended December 31, 2025, showing mixed performance with quarterly losses offset by nine-month profitability. The Mumbai-based diagnostics company's Board of Directors approved the results at a meeting held on February 10, 2026.
Q3FY26 Financial Performance
The company reported a significant quarterly loss, marking a sharp reversal from the previous year's performance. Total expenses exceeded income, leading to operational challenges during the quarter.
| Metric | Q3FY26 | Q3FY25 | Change |
|---|---|---|---|
| Revenue from Operations | ₹511.88 lakhs | ₹540.74 lakhs | -5.33% |
| Total Income | ₹524.83 lakhs | ₹549.61 lakhs | -4.51% |
| Total Expenses | ₹680.95 lakhs | ₹511.94 lakhs | +33.01% |
| Net Profit/(Loss) | ₹(156.12) lakhs | ₹37.66 lakhs | Loss |
| Basic EPS | ₹(1.52) | ₹0.37 | Loss |
Nine-Month Performance Analysis
Despite quarterly challenges, the company maintained profitability for the nine-month period, though at reduced levels compared to the previous year. Revenue growth was positive, but margin compression affected overall profitability.
| Parameter | 9M FY26 | 9M FY25 | Growth |
|---|---|---|---|
| Revenue from Operations | ₹1,845.96 lakhs | ₹1,622.23 lakhs | +13.79% |
| Total Income | ₹1,883.63 lakhs | ₹1,647.85 lakhs | +14.31% |
| Net Profit | ₹74.03 lakhs | ₹135.02 lakhs | -45.17% |
| Basic EPS | ₹0.72 | ₹1.31 | -45.04% |
Expense Structure and Cost Analysis
The company's expense structure showed significant increases across multiple categories during Q3FY26. Employee benefits expense rose to ₹245.07 lakhs from ₹196.57 lakhs in Q3FY25, while other expenses increased substantially to ₹240.79 lakhs from ₹160.07 lakhs year-on-year.
Key expense components for Q3FY26 included:
- Cost of materials consumed: ₹112.19 lakhs
- Laboratory testing charges: ₹34.86 lakhs
- Finance costs: ₹9.81 lakhs
- Depreciation and amortisation: ₹38.23 lakhs
Corporate Developments
The Board of Directors approved a material related party transaction between the company and Yashraj Research Foundation for sale of services worth ₹5 crores, subject to member approval. This transaction requires shareholder consent as per regulatory requirements.
Regulatory Compliance and Governance
The financial results were reviewed by the Audit Committee and approved by the Board of Directors in compliance with SEBI LODR Regulations, 2015. The results underwent limited review by statutory auditors Sarda Soni Associates LLP, who provided an unmodified opinion. The company maintains a paid-up equity share capital of ₹1,029.30 lakhs with face value of ₹10 per share.
The company noted the impact of new labour codes notified by the Government of India in November 2025, resulting in an increase in gratuity liability of ₹12 lakhs disclosed under employee benefits expenses.
Historical Stock Returns for Aspira Pathlab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -100.00% | -100.00% | -100.00% | -100.00% | -100.00% | -100.00% |
20
